These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 20616724)

  • 1. Generation of MHC class II-peptide ligands for CD4 T-cell allorecognition of MHC class II molecules.
    Leddon SA; Sant AJ
    Curr Opin Organ Transplant; 2010 Aug; 15(4):505-11. PubMed ID: 20616724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling alternative binding registers of a minimal immunogenic peptide on two class II major histocompatibility complex (MHC II) molecules predicts polarized T-cell receptor (TCR) contact positions.
    Murray JS; Fois SD; Schountz T; Ford SR; Tawde MD; Brown JC; Siahaan TJ
    J Pept Res; 2002 Mar; 59(3):115-22. PubMed ID: 11985705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor.
    Sant'Angelo DB; Robinson E; Janeway CA; Denzin LK
    Eur J Immunol; 2002 Sep; 32(9):2510-20. PubMed ID: 12207335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The alloreactive and self-restricted CD4+ T cell response directed against a single MHC class II/peptide combination.
    Kovalik JP; Singh N; Mendiratta SK; Martin WD; Ignatowicz L; Van Kaer L
    J Immunol; 2000 Aug; 165(3):1285-93. PubMed ID: 10903728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The crystal structure of a T cell receptor in complex with peptide and MHC class II.
    Reinherz EL; Tan K; Tang L; Kern P; Liu J; Xiong Y; Hussey RE; Smolyar A; Hare B; Zhang R; Joachimiak A; Chang HC; Wagner G; Wang J
    Science; 1999 Dec; 286(5446):1913-21. PubMed ID: 10583947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The orientation of a T cell receptor to its MHC class II:peptide ligands.
    Hong SC; Sant'Angelo DB; Dittel BN; Medzhitov R; Yoon ST; Waterbury PG; Janeway CA
    J Immunol; 1997 Nov; 159(9):4395-402. PubMed ID: 9379037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A previously unappreciated polymorphism in the beta chain of I-A
    Richards KA; Lavery C; Keller GLJ; Miller J; Baker BM; Sant AJ
    Mol Immunol; 2022 Mar; 143():17-26. PubMed ID: 34995990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis.
    Murphy B; Magee CC; Alexander SI; Waaga AM; Snoeck HW; Vella JP; Carpenter CB; Sayegh MH
    J Clin Invest; 1999 Mar; 103(6):859-67. PubMed ID: 10079107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of CD4 T cell function by soluble MHC II-peptide chimeras.
    Casares S; Bona CA; Brumeanu TD
    Int Rev Immunol; 2001 Oct; 20(5):547-73. PubMed ID: 11890612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The structural basis of T-cell allorecognition.
    Whitelegg A; Barber LD
    Tissue Antigens; 2004 Feb; 63(2):101-8. PubMed ID: 14705981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ T cells mature in the absence of MHC class I and class II expression in Ly-6A.2 transgenic mice.
    Henderson SC; Berezovskaya A; English A; Palliser D; Rock KL; Bamezai A
    J Immunol; 1998 Jul; 161(1):175-82. PubMed ID: 9647222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presentation of a self-peptide for in vivo tolerance induction of CD4+ T cells is governed by a processing factor that maps to the class II region of the major histocompatibility complex locus.
    Fedoseyeva EV; Tam RC; Orr PL; Garovoy MR; Benichou G
    J Exp Med; 1995 Nov; 182(5):1481-91. PubMed ID: 7595218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide dependency of alloreactive CD4+ T cell responses.
    Mendiratta SK; Kovalik JP; Hong S; Singh N; Martin WD; Van Kaer L
    Int Immunol; 1999 Mar; 11(3):351-60. PubMed ID: 10221647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4-Ia interactions can occur in the absence of T-cell receptor/antigen-Ia recognition.
    Andris F; Leo O; Van Mechelen M; Urbain J; Slaoui M
    Immunology; 1989 Sep; 68(1):1-6. PubMed ID: 2530152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of bispecific heteroconjugated antibodies (anti-T cell antigen receptor x anti-MHC class II) to study activation of T cells with a full length or truncated antigen receptor zeta-chain.
    Wu S; Yang Y; Sadegh-Nasseri S; Ashwell JD
    J Immunol; 1993 Mar; 150(6):2211-21. PubMed ID: 8450208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell selection and differential activation on structurally related HLA-DR4 ligands.
    Gebe JA; Novak EJ; Kwok WW; Farr AG; Nepom GT; Buckner JH
    J Immunol; 2001 Sep; 167(6):3250-6. PubMed ID: 11544312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Coreceptor function of CD4 in response to MHC class I molecule].
    Zvezdova ES; Grinenko TS; Pobezinskaia EL; Pobezinskiĭ LA; Kazanskiĭ DB
    Mol Biol (Mosk); 2008; 42(4):662-72. PubMed ID: 18856067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A basis for alloreactivity: MHC helical residues broaden peptide recognition by the TCR.
    Daniel C; Horvath S; Allen PM
    Immunity; 1998 May; 8(5):543-52. PubMed ID: 9620675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MHC class II-dependent peptide antigen versus superantigen presentation to T cells.
    Shoukry NH; Lavoie PM; Thibodeau J; D'Souza S; Sekaly RP
    Hum Immunol; 1997 May; 54(2):194-201. PubMed ID: 9297538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide specificity of alloreactive CD4 positive T lymphocytes directed against a major histocompatibility complex class I disparity.
    Ossevoort MA; De Bruijn ML; Van Veen KJ; Kast WM; Melief CJ
    Transplantation; 1996 Nov; 62(10):1485-91. PubMed ID: 8958276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.